[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1121794T1 - Ποντικος κοινης ελαφριας αλυσου - Google Patents

Ποντικος κοινης ελαφριας αλυσου

Info

Publication number
CY1121794T1
CY1121794T1 CY20191100710T CY191100710T CY1121794T1 CY 1121794 T1 CY1121794 T1 CY 1121794T1 CY 20191100710 T CY20191100710 T CY 20191100710T CY 191100710 T CY191100710 T CY 191100710T CY 1121794 T1 CY1121794 T1 CY 1121794T1
Authority
CY
Cyprus
Prior art keywords
light chain
mouse
chain variable
human
constant
Prior art date
Application number
CY20191100710T
Other languages
English (en)
Inventor
John Mcwhirter
Lynn Macdonald
Sean Stevens
Samuel Davis
Andrew J. Murphy
David R. Buckler
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43663643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121794(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of CY1121794T1 publication Critical patent/CY1121794T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Παρέχεται ένας γενετικά τροποποιημένος ποντικός, όπου ο ποντικός είναι ανίκανος να αναδιατάξει και εκφράσει μία ενδογενή μεταβλητή αλληλουχία ελαφριάς αλύσου ανοσοσφαιρίνης ποντικού, όπου ο ποντικός εκφράζει μόνο ένα ή δύο μεταβλητά πεδία ελαφριάς αλύσου ανθρώπου που κωδικοποιούνται από αλληλουχίες ανοσοσφαιρίνης ανθρώπου λειτουργικά συνδεδεμένες με το σταθερό γονίδιο κάπα (κ) ποντικού στον ενδογενή τόπο κ ποντικού, όπου ο ποντικός εκφράζει ένα αντίστροφο χιμαιρικό αντίσωμα έχον ένα μεταβλητό πεδίο ελαφριάς αλύσου προερχόμενο από ένα εκ δύο μόνο γονιδιακών τμημάτων μεταβλητής περιοχής ελαφριάς αλύσου ανθρώπου και ένα σταθερό πεδίο κ ποντικού και ένα μεταβλητό πεδίο βαριάς αλύσου ανθρώπου και ένα σταθερό πεδίο βαριάς αλύσου ποντικού από ένα ενδογενή τόπο βαριάς αλύσου ποντικού. Παρέχονται πρωτεΐνες δεσμεύσεως του επιτόπου διπλής ειδικότητας που είναι πλήρως ανθρώπινες που περιλαμβάνουν δύο διαφορετικές βαριές αλύσους που σχετίζονται με μία ταυτόσημη ελαφριά άλυσο που περιλαμβάνει ένα μεταβλητό πεδίο προερχόμενο από ένα εκ δύο διαφορετικών γονιδιακών τμημάτων μεταβλητής περιοχής ελαφριάς αλύσου ανθρώπου.
CY20191100710T 2010-02-08 2019-07-05 Ποντικος κοινης ελαφριας αλυσου CY1121794T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30228210P 2010-02-08 2010-02-08
EP11703799.4A EP2501817B2 (en) 2010-02-08 2011-02-08 Common light chain mouse
EP12173456.0A EP2505654B2 (en) 2010-02-08 2011-02-08 Common light chain mouse
PCT/US2011/023971 WO2011097603A1 (en) 2010-02-08 2011-02-08 Common light chain mouse

Publications (1)

Publication Number Publication Date
CY1121794T1 true CY1121794T1 (el) 2020-07-31

Family

ID=43663643

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20161101191T CY1118241T1 (el) 2010-02-08 2016-11-17 Ποντικος κοινης ελαφριας αλυσου
CY20191100710T CY1121794T1 (el) 2010-02-08 2019-07-05 Ποντικος κοινης ελαφριας αλυσου

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20161101191T CY1118241T1 (el) 2010-02-08 2016-11-17 Ποντικος κοινης ελαφριας αλυσου

Country Status (30)

Country Link
US (5) US10143186B2 (el)
EP (4) EP2501817B2 (el)
JP (8) JP5955781B2 (el)
KR (5) KR101829691B1 (el)
CN (2) CN105010238B (el)
AU (1) AU2011213585B2 (el)
BR (2) BR112012019887B1 (el)
CA (1) CA2789154C (el)
CY (2) CY1118241T1 (el)
DK (3) DK3095871T3 (el)
ES (3) ES2603559T5 (el)
HK (2) HK1231505A1 (el)
HR (3) HRP20151188T4 (el)
HU (3) HUE045591T2 (el)
IL (3) IL221265B (el)
LT (2) LT3095871T (el)
ME (2) ME02646B (el)
MX (3) MX2012009168A (el)
MY (1) MY166529A (el)
NZ (4) NZ631363A (el)
PL (3) PL2501817T5 (el)
PT (3) PT2501817E (el)
RS (3) RS59001B1 (el)
RU (2) RU2571205C2 (el)
SG (4) SG10201500821UA (el)
SI (3) SI3095871T1 (el)
SM (2) SMT201500283B (el)
TR (1) TR201906650T4 (el)
WO (1) WO2011097603A1 (el)
ZA (1) ZA201205944B (el)

Families Citing this family (198)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
CN101537180B (zh) 2002-07-18 2016-02-10 莫鲁斯有限公司 抗体混合物的重组生产
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
SG174053A1 (en) 2006-09-01 2011-09-29 Therapeutic Human Polyclonals Inc Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
LT3456190T (lt) * 2008-06-27 2022-03-10 Merus N.V. Antikūną produkuojantis transgeninis pelių pošeimio gyvūnas
CN107549118B (zh) 2008-12-18 2022-06-24 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
DK2564695T3 (en) 2009-07-08 2015-05-26 Kymab Ltd Animal models and therapeutic molecules
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
KR101829691B1 (ko) * 2010-02-08 2018-02-19 리제너론 파마슈티칼스 인코포레이티드 일반적인 경쇄 마우스
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US20120021409A1 (en) * 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
SI3034608T1 (sl) * 2010-06-22 2019-06-28 Regeneron Pharmaceuticals, Inc. Miši, ki izražajo hibridno lahko verigo imunoglobulina s humano variabilno regijo
EP2947151A1 (en) 2010-08-02 2015-11-25 Regeneron Pharmaceuticals, Inc. Binding proteins comprising vl domains
CN103348012B (zh) * 2010-11-27 2016-06-08 朱坚 一种人源化的转基因动物
HUE046746T2 (hu) 2011-02-25 2020-03-30 Regeneron Pharma Adam6 egér
KR101572338B1 (ko) 2011-02-28 2015-11-26 에프. 호프만-라 로슈 아게 1가 항원 결합 단백질
KR101638224B1 (ko) 2011-02-28 2016-07-08 에프. 호프만-라 로슈 아게 항원 결합 단백질
WO2013022782A1 (en) * 2011-08-05 2013-02-14 Regeneron Pharmaceuticals, Inc. Humanized universal light chain mice
EP2758534B1 (en) * 2011-09-19 2020-04-29 Kymab Limited Animals, repertoires & methods for the production of human antibodies
EP2758535B1 (en) 2011-09-19 2016-11-09 Kymab Limited Antibodies, variable domains&chains tailored for human use
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
GB2495083A (en) * 2011-09-26 2013-04-03 Kymab Ltd Human VpreB and chimaeric surrogate light chains in transgenic non-human vertebrates
SI2760471T1 (sl) * 2011-09-30 2017-04-26 Dana-Farber Cancer Institute, Inc. Terapevtski peptidi
PT3216871T (pt) 2011-10-17 2022-03-15 Regeneron Pharma Ratos com cadeia pesada de imunoglobulina restrita
EP2770823A4 (en) 2011-10-28 2015-12-09 Trianni Inc TRANSGENIC ANIMALS AND METHOD FOR THEIR USE
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
WO2013096142A1 (en) 2011-12-20 2013-06-27 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
BR112014021251A2 (pt) 2012-03-02 2017-06-27 Regeneron Pharma anticorpos humanos para toxinas de clostridium difficile
CN107090471A (zh) * 2012-03-06 2017-08-25 瑞泽恩制药公司 共同轻链小鼠
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
AU2015227453B2 (en) * 2012-03-16 2017-05-25 Regeneron Pharmaceuticals, Inc. Non-human animals expressing ph-sensitive immunoglobulin sequences
HUE053310T2 (hu) 2012-03-16 2021-06-28 Regeneron Pharma Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ugyanennek az elõállítására
CN107361011B (zh) * 2012-03-16 2021-08-27 瑞泽恩制药公司 制备表达ph敏感性免疫球蛋白序列的非人动物的方法
US9301510B2 (en) * 2012-03-16 2016-04-05 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with pH-dependent binding characteristics
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
SG10201913376XA (en) * 2012-04-20 2020-02-27 Merus Nv Methods and means for the production of ig-like molecules
DK2847231T3 (da) * 2012-05-10 2019-10-14 Bioatla Llc Multispecifikke monoklonale antistoffer
CA2874846A1 (en) * 2012-06-05 2013-12-12 Regeneron Pharmaceuticals, Inc. Methods for making fully human bispecific antibodies using a common light chain
EP3912464A1 (en) 2012-06-12 2021-11-24 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JO3462B1 (ar) 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
ES2692951T3 (es) 2012-09-27 2018-12-05 Merus N.V. Anticuerpos IgG biespecíficos como acopladores de células T
CN105051069B (zh) 2013-01-14 2019-12-10 Xencor股份有限公司 新型异二聚体蛋白
PT2958938T (pt) * 2013-02-20 2019-07-23 Regeneron Pharma Ratinhos que expressam correcetores de células t humanizados
RU2017114166A (ru) * 2013-02-20 2019-01-29 Регенерон Фармасьютикалс, Инк. Не являющиеся человеком животные с модифицированными последовательностями тяжелых цепей иммуноглобулинов
KR102211267B1 (ko) * 2013-02-22 2021-02-04 리제너론 파아마슈티컬스, 인크. 사람화된 주요 조직적합성 복합체를 발현하는 마우스
KR102309653B1 (ko) * 2013-03-11 2021-10-08 리제너론 파아마슈티컬스, 인크. 키메라 주요 조직적합성 복합체 （ｍｈｃ） 제ｉｉ부류 분자를 발현하는 유전자전이 마우스
EP2970437A1 (en) * 2013-03-13 2016-01-20 Regeneron Pharmaceuticals, Inc. Common light chain mouse
BR112015022034B1 (pt) * 2013-03-13 2023-02-28 Regeneron Pharmaceuticals, Inc Método de fabricar um camundongo, e, para fabricar um anticorpo
WO2014141189A1 (en) 2013-03-14 2014-09-18 Erasmus University Medical Center Transgenic non-human mammal for antibody production
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
SG11201508911PA (en) 2013-04-29 2015-11-27 Hoffmann La Roche Human fcrn-binding modified antibodies and methods of use
US20150033372A1 (en) * 2013-05-01 2015-01-29 Kymab Limited Human VpreB & Chimaeric Surrogate Light Chains in Transgenic Non-Human Vertebrates
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
EP3046412B1 (en) 2013-09-18 2019-04-10 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
MX2016003617A (es) 2013-09-30 2016-07-21 Chugai Pharmaceutical Co Ltd Metodo para producir molecula de enlace al antigeno usando fago auxiliar modificado.
CN105683365A (zh) * 2013-10-01 2016-06-15 科马布有限公司 动物模型及治疗分子
CN105612182B (zh) 2013-10-11 2019-12-10 豪夫迈·罗氏有限公司 多特异性结构域交换共有可变轻链抗体
JP6786392B2 (ja) 2014-01-15 2020-11-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＦｃＲｎ結合特性が改変され、プロテインＡ結合特性が保持されているＦｃ領域変異体
KR20160104636A (ko) 2014-01-15 2016-09-05 에프. 호프만-라 로슈 아게 단백질 Ａ-결합이 개선된 Ｆｃ-영역 변이체
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
CA2941077A1 (en) 2014-02-28 2015-09-03 Merus N.V. Antibody that binds erbb-2 and erbb-3
US10844127B2 (en) 2014-02-28 2020-11-24 Merus N.V. Antibodies that bind EGFR and ErbB3
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
EP3119811B1 (en) 2014-03-21 2019-10-30 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
SG10201808225TA (en) 2014-03-21 2018-10-30 Regeneron Pharma Non-human animals that make single domain binding proteins
MY186389A (en) 2014-05-13 2021-07-22 Univ Pennsylvania Compositions comprising aav expressing dual antibody constructs and uses thereof
ES2901705T3 (es) 2014-06-06 2022-03-23 Bristol Myers Squibb Co Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (GITR) y usos de los mismos
SG11201701040XA (en) 2014-09-19 2017-03-30 Regeneron Pharma Chimeric antigen receptors
AU2015327819B2 (en) 2014-10-03 2021-07-01 Massachusetts Institute Of Technology Antibodies that bind ebola glycoprotein and uses thereof
KR20170076697A (ko) 2014-11-06 2017-07-04 에프. 호프만-라 로슈 아게 개질된 FCRN-결합 특성 및 단백질 A-결합 특성을 가진 Fc-영역 변이체
SI3221359T1 (sl) 2014-11-17 2020-08-31 Regeneron Pharmaceuticals, Inc. Metode zravljenja tumorja z uporabo bispecifičnega protitelesa CD3XCD20
ES2807182T3 (es) 2014-11-21 2021-02-22 Bristol Myers Squibb Co Anticuerpos frente a CD73 y sus usos
HUE055115T2 (hu) 2014-11-26 2021-10-28 Xencor Inc CD3-at és CD20-at kötõ heterodimer antitestek
SG11201704274QA (en) 2014-11-26 2017-06-29 Xencor Inc Heterodimeric antibodies that bind cd3 and cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CN107278206B (zh) 2014-12-19 2021-04-02 雷根尼桑斯公司 结合人c6的抗体及其用途
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
MA40662B1 (fr) 2014-12-23 2020-12-31 Bristol Myers Squibb Co Anticorps contre tigit
EP3271403A1 (en) * 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
SG10202008304TA (en) 2015-05-29 2020-10-29 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof
WO2017004016A1 (en) 2015-06-29 2017-01-05 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
ES2971045T3 (es) 2015-07-06 2024-06-03 Regeneron Pharma Moléculas multiespecíficas de unión a antígeno y usos de las mismas
HUE042039T2 (hu) 2015-07-10 2019-06-28 Merus Nv Humán CD3 kötõ antitest
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
JP7023231B2 (ja) 2015-09-23 2022-02-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 最適化抗ｃｄ３二重特異性抗体及びその使用
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
ES2865482T3 (es) 2015-10-23 2021-10-15 Merus Nv Moléculas de unión que inhiben el crecimiento del cáncer
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
HRP20231156T1 (hr) 2015-12-22 2024-01-05 Regeneron Pharmaceuticals, Inc. Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka
MX2018008701A (es) 2016-01-13 2019-06-06 Regeneron Pharma Roedores que tienen una region de diversidad de cadena pesada modificada geneticamente.
SG10201913033UA (en) 2016-03-04 2020-03-30 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
CA3016534A1 (en) 2016-03-04 2017-09-08 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
EP3448891A1 (en) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
SG11201809793UA (en) 2016-05-09 2018-12-28 Bristol Myers Squibb Co Tl1a antibodies and uses thereof
TW202408578A (zh) 2016-05-13 2024-03-01 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
MX2018014172A (es) 2016-05-20 2019-08-22 Regeneron Pharma Métodos para romper la tolerancia inmunológica usando múltiples arn guías.
EP4218408A1 (en) 2016-06-03 2023-08-02 Regeneron Pharmaceuticals, Inc. Rodents expressing exogenous terminal deoxynucleotidyltransferase
FI3468990T3 (fi) 2016-06-14 2024-06-26 Regeneron Pharma Anti-C5-vasta-aineita ja niiden käyttöjä
SG11201811490XA (en) * 2016-06-21 2019-01-30 Teneobio Inc Cd3 binding antibodies
CN109715663B (zh) 2016-06-28 2022-11-25 Xencor股份有限公司 结合生长抑素受体2的异源二聚抗体
MX2019000443A (es) 2016-07-14 2019-06-20 Squibb Bristol Myers Co Anticuerpos contra proteina 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos t (tim3) y sus usos.
UY37377A (es) 2016-08-26 2018-03-23 Sanofi Sa Anticuerpos multiespecíficos que facilitan el emparejamiento selectivo de cadenas ligeras
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
JP7030109B2 (ja) * 2016-09-14 2022-03-04 テネオバイオ， インコーポレイテッド Ｃｄ３結合抗体
PT3515487T (pt) 2016-09-23 2023-08-24 Regeneron Pharma Anticorpos anti-muc16-cd3 biespecíficos e conjugados antimuc16- fármacos
SG10202102617QA (en) 2016-09-23 2021-04-29 Regeneron Pharma Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
US11267873B2 (en) 2016-10-13 2022-03-08 Massachusetts Institute Of Technology Antibodies that bind zika virus envelope protein and uses thereof
IL313695A (en) 2017-02-10 2024-08-01 Regeneron Pharma Radiolabeled anti-LAG3 antibodies for immuno-PET imaging
EP3583124A1 (en) 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
CN118063619A (zh) 2017-03-02 2024-05-24 诺华股份有限公司 工程化的异源二聚体蛋白质
AU2018246873B2 (en) 2017-03-31 2021-05-06 Merus N.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
CN117567624A (zh) 2017-06-20 2024-02-20 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
CN117866097A (zh) 2017-06-20 2024-04-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
GB201710984D0 (en) * 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
TW202348250A (zh) 2017-07-24 2023-12-16 美商再生元醫藥公司 穩定化之抗體組合物及其製法
CN118562014A (zh) 2017-08-09 2024-08-30 美勒斯公司 结合EGFR和cMET的抗体
AU2018341587A1 (en) 2017-09-29 2020-04-23 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof
KR20200098528A (ko) 2017-12-13 2020-08-20 리제너론 파아마슈티컬스, 인크. 항-c5 항체 조합물 및 이의 용도
EP3728319A1 (en) 2017-12-22 2020-10-28 TeneoBio, Inc. Heavy chain antibodies binding to cd22
EP3737700A1 (en) 2018-01-12 2020-11-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2019147867A1 (en) 2018-01-26 2019-08-01 Regeneron Pharmaceuticals, Inc. Human antibodies to influenza hemagglutinin
PE20210665A1 (es) 2018-03-23 2021-03-31 Bristol Myers Squibb Co Anticuerpos contra mica y/o micb y sus usos
CN112040769B (zh) 2018-03-24 2023-05-16 瑞泽恩制药公司 用于产生针对肽-mhc复合物的治疗抗体的经过基因修饰的非人动物、制造方法和用途
MX2020011487A (es) 2018-04-30 2020-12-07 Regeneron Pharma Anticuerpos y moleculas biespecificas de union al antigeno que se unen a her2 y/o aplp2, conjugados y usos de estos.
US20210079109A1 (en) 2018-05-17 2021-03-18 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
WO2019241692A1 (en) 2018-06-14 2019-12-19 Regeneron Pharmaceuticals, Inc. Non-human animals capable of dh-dh rearrangement in the immunoglobulin heavy chain coding sequences
MX2020013804A (es) 2018-06-21 2021-03-31 Regeneron Pharma Anticuerpos anti-psma x anti-cd28 biespecíficos y usos de estos.
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
US11578127B2 (en) 2018-08-23 2023-02-14 Regeneron Pharmaceuticals, Inc. Anti-Fc epsilon-R1 alpha (FcεR1α) antibodies, bispecific antigen-binding molecules that bind FcεR1α and CD3, and uses thereof
IL280875B1 (en) 2018-08-31 2024-08-01 Regeneron Pharma Cytokine Release Syndrome Attenuating Dosing Strategy for Bispecific Antibodies to CD3 and CD20
US11306148B2 (en) 2018-10-23 2022-04-19 Regeneron Pharmaceuticals, Inc. Anti-NPR1 antibodies and uses thereof
CA3119838A1 (en) 2018-11-16 2020-05-22 Bristol-Myers Squibb Company Anti-nkg2a antibodies and uses thereof
EP3883961A1 (en) 2018-11-20 2021-09-29 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
MA55134A (fr) 2018-11-21 2021-09-29 Regeneron Pharma Anticorps anti-staphylococcus et leurs utilisations
MX2021006971A (es) 2018-12-19 2021-07-15 Regeneron Pharma Anticuerpos anti-muc16 x anti-cd28 biespecificos y usos de estos.
WO2020132066A1 (en) 2018-12-19 2020-06-25 Regeneron Pharmaceuticals, Inc. Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof
WO2020132557A1 (en) 2018-12-21 2020-06-25 Compass Therapeutics Llc Transgenic mouse expressing common human light chain
CN113396162B (zh) 2019-01-22 2024-08-16 百时美施贵宝公司 抗IL-7Rα亚基的抗体及其用途
CA3125380A1 (en) 2019-02-18 2020-08-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
CA3127153A1 (en) 2019-02-22 2020-08-27 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
AU2020247803A1 (en) 2019-03-22 2021-11-11 Regeneron Pharmaceuticals, Inc. EGFR x CD28 multispecific antibodies
CA3136478A1 (en) 2019-06-05 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
AU2020292283A1 (en) 2019-06-11 2021-12-23 Regeneron Pharmaceuticals, Inc. Anti-PcrV antibodies that bind PcrV, compositions comprising anti-PcrV antibodies, and methods of use thereof
EA202290054A1 (ru) 2019-06-14 2022-03-25 Тенеобио, Инк. Полиспецифические антитела, содержащие только тяжелые цепи, которые связываются с cd22 и cd3
AU2020294790A1 (en) 2019-06-21 2021-12-16 Regeneron Pharmaceuticals, Inc. Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation
JP2022537019A (ja) 2019-06-21 2022-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｐｓｍａおよびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用
WO2021026409A1 (en) 2019-08-08 2021-02-11 Regeneron Pharmaceuticals, Inc. Novel antigen binding molecule formats
EP4013797A1 (en) 2019-08-15 2022-06-22 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules for cell targeting and uses thereof
GB201912008D0 (en) 2019-08-21 2019-10-02 Cambridge Entpr Ltd Antibody
KR20220088446A (ko) 2019-10-28 2022-06-27 리제너론 파마슈티칼스 인코포레이티드 항-헤마글루티닌 항체 및 이의 사용 방법
IL293330A (en) 2019-12-02 2022-07-01 Regeneron Pharma mhc ii peptide protein structures and uses thereof
EP4069373A1 (en) 2019-12-06 2022-10-12 Regeneron Pharmaceuticals, Inc. Methods of treating multiple myeloma with bispecific anti-bcma x anti-cd3 antibodies
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
AU2021218675A1 (en) 2020-02-11 2022-08-18 Regeneron Pharmaceuticals, Inc. Anti-ACVR1 antibodies and uses thereof
CN115715220A (zh) 2020-04-29 2023-02-24 特尼奥生物股份有限公司 具有经修饰重链恒定区的多特异性重链抗体
IL298099A (en) 2020-05-12 2023-01-01 Regeneron Pharma Antibodies against glp1r agonist and methods of using them
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
CN115667532A (zh) 2020-06-02 2023-01-31 百奥赛图(北京)医药科技股份有限公司 具有共有轻链免疫球蛋白基因座的经遗传修饰的非人动物
IL300666A (en) 2020-08-19 2023-04-01 Xencor Inc ANTI–CD28 COMPOSITIONS
WO2022056276A1 (en) 2020-09-11 2022-03-17 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
EP4214234A1 (en) 2020-09-18 2023-07-26 Regeneron Pharmaceuticals, Inc. Antigen-binding molecules that bind cd38 and/or cd28, and uses thereof
US11866502B2 (en) 2020-10-22 2024-01-09 Regeneron Pharmaceuticals, Inc. Anti-FGFR2 antibodies and methods of use thereof
CN118878694A (zh) 2020-11-23 2024-11-01 康诺亚生物医药科技（成都）有限公司 一种双特异性抗体及其用途
CA3199879A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
US20220195014A1 (en) 2020-12-23 2022-06-23 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
CN116635413A (zh) 2020-12-23 2023-08-22 再生元制药公司 用于获得结合跨膜蛋白的抗体的方法和生产所述抗体的细胞
MX2023008949A (es) 2021-01-28 2023-10-23 Regeneron Pharma Composiciones y metodos para tratar el sindrome de liberacion de citocinas.
US11739144B2 (en) 2021-03-09 2023-08-29 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CLDN6
WO2022192586A1 (en) 2021-03-10 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
MX2024006812A (es) 2021-12-06 2024-08-19 Regeneron Pharma Anticuerpos antagonistas anti-npr1 y metodos de uso de los mismos.
TW202400228A (zh) 2022-02-25 2024-01-01 美商再生元醫藥公司 減輕細胞激素釋放症候群的給藥方案
WO2023196903A1 (en) 2022-04-06 2023-10-12 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof
US20230357446A1 (en) 2022-04-11 2023-11-09 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
WO2023225098A1 (en) 2022-05-18 2023-11-23 Regeneron Pharmaceuticals, Inc. Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof
WO2024015816A1 (en) 2022-07-12 2024-01-18 Regeneron Pharmaceuticals, Inc. Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof
WO2024092133A1 (en) 2022-10-27 2024-05-02 Regeneron Pharmaceuticals, Inc. Anti-acvr1 antibodies and their use in the treatment of trauma-induced heterotopic ossification
GB202217978D0 (en) * 2022-11-30 2023-01-11 Petmedix Ltd Rodents expressing a common light chain
TW202430641A (zh) 2023-01-18 2024-08-01 美商基利科學股份有限公司 人類免疫球蛋白二元輕鏈轉殖基因構築體及其用途
WO2024163477A1 (en) 2023-01-31 2024-08-08 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
WO2024173248A1 (en) 2023-02-13 2024-08-22 Regeneron Pharmaceuticals, Inc. Treatment of muscle related disorders with anti-human cacng1 antibodies
WO2024173830A2 (en) 2023-02-17 2024-08-22 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE190355T1 (de) 1988-09-06 2000-03-15 Xoma Corp Genexpressions-elemente und herstellung von chimären maus-mensch-antikörpern
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US5574205A (en) 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP0502976B1 (en) 1989-12-01 1996-07-03 Pharming B.V. Production of recombinant polypeptides by bovine species and transgenic methods
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) * 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
ATE158021T1 (de) † 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US7067284B1 (en) 1992-01-27 2006-06-27 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
AU675661B2 (en) 1992-07-24 1997-02-13 Abgenix, Inc. Generation of xenogeneic antibodies
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
ATE213771T1 (de) 1993-12-23 2002-03-15 Infigen Inc Embryonale stammzellen von huftieren als kerndonatoren und kerntransfertechniken zur herstellung chimärer und transgener tiere
EP0744958B1 (en) 1994-01-31 2003-06-25 Trustees Of Boston University Polyclonal antibody libraries
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ATE218143T1 (de) 1996-09-03 2002-06-15 Gsf Forschungszentrum Umwelt Verwendung bi-und trispezifischer antikörper zur induktion einer tumorimmunität
WO1998024893A2 (en) 1996-12-03 1998-06-11 Abgenix, Inc. TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM
NZ337495A (en) 1997-03-06 2001-06-29 Infigen Inc Bovine primordial germ cells and their use in cloning
PT970126E (pt) 1997-04-14 2001-10-30 Micromet Ag Novo metodo para a producao de receptores de antigenios anti-humanos e suas utilizacoes
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
WO1998050431A2 (en) 1997-05-02 1998-11-12 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
AU750453B2 (en) 1997-10-03 2002-07-18 Chugai Seiyaku Kabushiki Kaisha Natural human antibody
ATE302271T1 (de) 1997-11-18 2005-09-15 Pioneer Hi Bred Int Zusammensetzungen und verfahren für die genetische modifizierung von pflanzen
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
ES2335775T3 (es) 1999-04-15 2010-04-05 Crucell Holland B.V. Produccion de protenia recombinante en una celula humana que comprende al menos una proteina e1 de adenovirus.
AU2001245358A1 (en) 2000-02-29 2001-09-12 Auburn University Production of antibodies in transgenic plastids
RU2262511C2 (ru) 2000-05-18 2005-10-20 Джапан Тобакко, Инк. Человеческое моноклональное антитело против ailim, костимулирующей молекулы передачи сигнала, и его фармацевтическое применение
WO2002008409A2 (en) 2000-07-21 2002-01-31 The United States Of America, As Represented By The Secretary Of Agriculture Methods for the replacement, translocation and stacking of dna in eukaryotic genomes
AU8470301A (en) 2000-08-03 2002-02-18 Wim-Van Schooten Production of humanized antibodies in transgenic animals
EP1184458A1 (en) 2000-08-28 2002-03-06 U-BISys B.V. Differentially expressed CD46 epitopes, proteinaceous molecules capable of binding thereto, and uses thereof
US20020119148A1 (en) 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
US6586251B2 (en) * 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AP2072A (en) 2001-01-05 2009-12-10 Pfizer Antibodies to insulin-like growth factor I receptor
US6961875B2 (en) 2001-03-22 2005-11-01 International Business Machines Corporation Method and apparatus for capturing event traces for debug and analysis
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
ATE477280T1 (de) 2001-06-28 2010-08-15 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
CA2491864C (en) 2001-07-12 2012-09-11 Jefferson Foote Super humanized antibodies
AU2002365196C1 (en) 2001-07-19 2009-08-13 Perlan Therapeutics, Inc. Multimeric proteins and methods of making and using same
PT1298207E (pt) 2001-10-01 2010-11-08 Deutsches Krebsforsch Processo para a produção de bibliotecas de proteínas e para a selecção de proteínas a partir da mesma
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
US20030108925A1 (en) 2001-10-05 2003-06-12 U.S. Epa Genetic testing for male factor infertility
CA2468565C (en) 2001-11-30 2014-06-03 Abgenix, Inc. Transgenic animals bearing human iglambda light chain genes
GB0130267D0 (en) 2001-12-19 2002-02-06 Neutec Pharma Plc Focussed antibody technology
AU2003214842A1 (en) 2002-01-17 2003-09-02 Albert Einstein College Of Medicine Of Yeshiva University Mutations caused by activation-induced cytidine deaminase
US20040052773A1 (en) 2002-01-18 2004-03-18 Inovio As Production of multi-chain protein from muscle
EP1505148B1 (en) 2002-04-26 2009-04-15 Chugai Seiyaku Kabushiki Kaisha Methods of screening for agonistic antibodies
WO2003106495A2 (en) 2002-06-14 2003-12-24 Immunomedics, Inc. MONOCLONAL ANTIBODY hPAM4
CN101962408A (zh) 2002-07-12 2011-02-02 杰斐逊·富特 超人源化抗体
CN101537180B (zh) * 2002-07-18 2016-02-10 莫鲁斯有限公司 抗体混合物的重组生产
AR042145A1 (es) 2002-11-27 2005-06-08 Dow Agrociences Llc Produccion de inmunoglobulinas en plantas con una fucocilacion reducida
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
EP1439234A1 (en) 2003-01-08 2004-07-21 ARTEMIS Pharmaceuticals GmbH Targeted transgenesis using the rosa26 locus
JP4477579B2 (ja) 2003-01-21 2010-06-09 中外製薬株式会社 抗体の軽鎖スクリーニング方法
CA2514517A1 (en) 2003-01-28 2004-08-12 Cellectis Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof
US20070009957A1 (en) 2003-03-04 2007-01-11 Alexion Pharmaceuticals, Inc. Vectors used to create hybrid constant regions
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US7585668B2 (en) 2003-07-15 2009-09-08 Therapeutic Human Polyclonals, Inc. Humanized immunoglobulin loci
WO2005019463A1 (en) 2003-08-11 2005-03-03 Therapeutic Human Polyclonals, Inc. Improved transgenesis with humanized immunoglobulin loci
WO2005038001A2 (en) 2003-10-14 2005-04-28 Therapeutic Human Polyclonals, Inc. Improved transgenesis by sperm-mediated gene transfer
WO2005070966A2 (en) 2004-01-16 2005-08-04 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
CN1560081A (zh) 2004-02-17 2005-01-05 大连帝恩生物工程有限公司 用能产生人IgGl重链－κ轻链小鼠作为制备人源化单克隆抗体和应用
US7625549B2 (en) 2004-03-19 2009-12-01 Amgen Fremont Inc. Determining the risk of human anti-human antibodies in transgenic mice
PT1802193E (pt) 2004-10-19 2014-06-23 Regeneron Pharma Método para gerar um murganho homozigótico para uma modificação genética
CN101084317A (zh) 2004-10-22 2007-12-05 人类多克隆治疗公司 对内源免疫球蛋白表达的抑制
CN101132811B (zh) 2004-10-22 2012-05-30 米迪缪尼有限公司 抗hmgb1的高亲和力抗体及其用法
JP2008538912A (ja) 2005-04-29 2008-11-13 イナート・ファルマ 遺伝子導入動物および組換え抗体の製造方法
CN101297031B (zh) 2005-05-14 2013-06-05 复旦大学 在脊椎动物中作为遗传操作和分析工具的piggyBac
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
WO2007065433A2 (en) * 2005-12-05 2007-06-14 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
SG169348A1 (en) 2006-01-25 2011-03-30 Univ Erasmus Medical Ct Generation of heavy-chain only antibodies in transgenic animals
US7462759B2 (en) 2006-02-03 2008-12-09 Pioneer Hi-Bred International, Inc. Brittle stalk 2 gene family and related methods and uses
EP2505058A1 (en) 2006-03-31 2012-10-03 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
BRPI0712224B8 (pt) 2006-06-02 2021-05-25 Regeneron Pharma anticorpos de alta afinidade para o receptor de il-6 humano e composições farmacêuticas
CN101501073A (zh) 2006-08-22 2009-08-05 G2英弗勒美欣私人有限公司 抗体制备方法
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
RS53340B (en) 2006-10-02 2014-10-31 Regeneron Pharmaceuticals, Inc. HIGH AFFINITY HUMAN ANTIBODIES FOR THE HUMAN IL-4 RECEPTOR
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
WO2009077483A1 (en) 2007-12-14 2009-06-25 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
GB0700194D0 (en) 2007-01-05 2007-02-14 Univ Edinburgh Humanisation of animals
EP2583551A1 (en) 2007-03-13 2013-04-24 National Jewish Health Methods for generation of antibodies
KR101886610B1 (ko) 2007-06-01 2018-08-09 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
WO2009013620A2 (en) 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
ITMI20071522A1 (it) * 2007-07-27 2009-01-28 Areta Internat S R L Vaccino idiotipico
US9693539B2 (en) 2007-08-10 2017-07-04 E. R. Squibb & Sons, L.L.C. HCO32 and HCO27 and related examples
EP2185701A4 (en) 2007-08-15 2011-03-02 Amunix Operating Inc COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES
MX2010002661A (es) 2007-09-14 2010-05-20 Adimab Inc Bancos de anticuerpos sinteticos, designados racionalmente y usos para los mismos.
US8536310B2 (en) 2007-10-17 2013-09-17 Arca Biopharma, Inc. Antibodies to CLL-1
PL2235064T3 (pl) 2008-01-07 2016-06-30 Amgen Inc Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
WO2009129247A2 (en) 2008-04-14 2009-10-22 Innovative Targeting Solutions Inc. Sequence diversity generation in immunoglobulins
US20110123527A1 (en) 2008-05-23 2011-05-26 Hiroaki Shizuya Method of generating single vl domain antibodies in transgenic animals
LT3456190T (lt) 2008-06-27 2022-03-10 Merus N.V. Antikūną produkuojantis transgeninis pelių pošeimio gyvūnas
CA2739038C (en) 2008-09-30 2020-04-28 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
DK2356270T3 (da) 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
CN107549118B (zh) 2008-12-18 2022-06-24 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
EP2401298A1 (en) 2009-02-24 2012-01-04 Glaxo Group Limited Antigen-binding constructs
CN102427978B (zh) 2009-05-07 2016-01-20 沃尔沃建筑设备公司 工程机械和用于操作工程机械的方法
ES2511051T3 (es) 2009-05-29 2014-10-22 Morphosys Ag Colección de anticuerpos sintéticos para tratar enfermedades
KR20120027055A (ko) 2009-06-26 2012-03-20 리제네론 파라마큐티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
DK2564695T3 (en) 2009-07-08 2015-05-26 Kymab Ltd Animal models and therapeutic molecules
JPWO2011062206A1 (ja) 2009-11-17 2013-04-04 協和発酵キリン株式会社 ヒト人工染色体ベクター
US8754287B2 (en) 2009-12-10 2014-06-17 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
KR101829691B1 (ko) 2010-02-08 2018-02-19 리제너론 파마슈티칼스 인코포레이티드 일반적인 경쇄 마우스
JP6022444B2 (ja) 2010-05-14 2016-11-09 ライナット ニューロサイエンス コーポレイション ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法
AU2011266843C9 (en) 2010-06-17 2018-03-01 Kymab Limited Animal models and therapeutic molecules
SI3034608T1 (sl) 2010-06-22 2019-06-28 Regeneron Pharmaceuticals, Inc. Miši, ki izražajo hibridno lahko verigo imunoglobulina s humano variabilno regijo
EP2947151A1 (en) 2010-08-02 2015-11-25 Regeneron Pharmaceuticals, Inc. Binding proteins comprising vl domains
HUE046746T2 (hu) 2011-02-25 2020-03-30 Regeneron Pharma Adam6 egér
WO2013022782A1 (en) 2011-08-05 2013-02-14 Regeneron Pharmaceuticals, Inc. Humanized universal light chain mice
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
PT3216871T (pt) 2011-10-17 2022-03-15 Regeneron Pharma Ratos com cadeia pesada de imunoglobulina restrita
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
CN107090471A (zh) 2012-03-06 2017-08-25 瑞泽恩制药公司 共同轻链小鼠
SG10201913376XA (en) 2012-04-20 2020-02-27 Merus Nv Methods and means for the production of ig-like molecules
CA2874846A1 (en) 2012-06-05 2013-12-12 Regeneron Pharmaceuticals, Inc. Methods for making fully human bispecific antibodies using a common light chain
BR112015022034B1 (pt) 2013-03-13 2023-02-28 Regeneron Pharmaceuticals, Inc Método de fabricar um camundongo, e, para fabricar um anticorpo
EP2970437A1 (en) 2013-03-13 2016-01-20 Regeneron Pharmaceuticals, Inc. Common light chain mouse

Also Published As

Publication number Publication date
SMT201600432B (it) 2017-01-10
WO2011097603A1 (en) 2011-08-11
SG183149A1 (en) 2012-09-27
HRP20151188T4 (hr) 2021-10-01
SG10201500821UA (en) 2015-04-29
KR20200060534A (ko) 2020-05-29
SI2505654T1 (sl) 2016-12-30
PT3095871T (pt) 2019-06-12
EP2501817B1 (en) 2015-08-26
JP6470789B2 (ja) 2019-02-13
ME02288B (me) 2016-02-20
MX350983B (es) 2017-09-27
HRP20161551T4 (hr) 2020-10-02
PL2505654T3 (pl) 2017-02-28
HK1231505A1 (zh) 2017-12-22
SI2505654T2 (sl) 2020-08-31
IL290085A (en) 2022-03-01
SI3095871T1 (sl) 2019-06-28
CN102791866B (zh) 2015-07-29
ES2728942T3 (es) 2019-10-29
US10143186B2 (en) 2018-12-04
HUE029785T2 (en) 2017-04-28
US20130302836A1 (en) 2013-11-14
HK1174358A1 (zh) 2013-06-07
KR20190077630A (ko) 2019-07-03
EP2505654B2 (en) 2020-05-13
RU2724663C2 (ru) 2020-06-25
RS54367B1 (en) 2016-04-28
BR122014002928A2 (pt) 2015-12-29
EP3095871B1 (en) 2019-04-10
ES2603559T3 (es) 2017-02-28
SG10201610294RA (en) 2017-02-27
DK2501817T4 (da) 2021-07-26
SI2501817T2 (sl) 2021-09-30
CY1118241T1 (el) 2017-06-28
IL267362A (en) 2019-08-29
JP2022001066A (ja) 2022-01-06
SI2501817T1 (sl) 2015-12-31
ME02646B (me) 2017-06-20
EP3095871A1 (en) 2016-11-23
MX2012009168A (es) 2012-08-31
RU2015147726A3 (el) 2019-06-25
DK3095871T3 (da) 2019-06-11
NZ601679A (en) 2014-01-31
US20110195454A1 (en) 2011-08-11
EP3540066A1 (en) 2019-09-18
RS55315B1 (sr) 2017-03-31
RS54367B2 (sr) 2021-08-31
RU2015147726A (ru) 2019-01-15
EP2505654A1 (en) 2012-10-03
HRP20151188T1 (hr) 2015-12-04
US20210204531A1 (en) 2021-07-08
MY166529A (en) 2018-07-10
RU2012138431A (ru) 2014-03-20
BR112012019887B1 (pt) 2021-06-08
CA2789154C (en) 2024-06-11
EP2501817A1 (en) 2012-09-26
PL2501817T3 (pl) 2016-02-29
JP2013518597A (ja) 2013-05-23
RU2571205C2 (ru) 2015-12-20
JP2017140050A (ja) 2017-08-17
KR20130010110A (ko) 2013-01-25
KR20210095730A (ko) 2021-08-02
PT2501817E (pt) 2015-11-04
IL221265B (en) 2020-04-30
US10986820B2 (en) 2021-04-27
JP2020096633A (ja) 2020-06-25
JP2019076108A (ja) 2019-05-23
RS59001B1 (sr) 2019-08-30
NZ619512A (en) 2014-10-31
CN105010238A (zh) 2015-11-04
ES2547142T5 (es) 2021-12-09
JP2018138047A (ja) 2018-09-06
ZA201205944B (en) 2013-06-26
AU2011213585B2 (en) 2014-02-06
BR112012019887A2 (pt) 2015-09-15
US20190040123A1 (en) 2019-02-07
NZ719253A (en) 2022-08-26
JP7538907B2 (ja) 2024-08-22
IL221265A0 (en) 2012-10-31
KR102116296B1 (ko) 2020-05-28
EP2505654B1 (en) 2016-08-24
ES2547142T3 (es) 2015-10-02
JP5955781B2 (ja) 2016-07-20
CN105010238B (zh) 2018-07-20
KR20180018838A (ko) 2018-02-21
PL3095871T3 (pl) 2019-10-31
JP7233504B2 (ja) 2023-03-06
DK2505654T4 (da) 2020-07-27
ES2603559T5 (es) 2021-02-22
KR101829691B1 (ko) 2018-02-19
HUE045591T2 (hu) 2019-12-30
JP6215264B2 (ja) 2017-10-18
HUE026229T2 (en) 2016-06-28
EP2501817B2 (en) 2021-04-21
KR102432611B1 (ko) 2022-08-16
PL2501817T5 (pl) 2021-08-16
SMT201500283B (it) 2016-01-08
JP6666483B2 (ja) 2020-03-13
NZ631363A (en) 2016-05-27
KR101995735B1 (ko) 2019-07-03
US20120192300A1 (en) 2012-07-26
SG10201913463QA (en) 2020-03-30
CN102791866A (zh) 2012-11-21
PT2505654T (pt) 2016-11-18
JP2023062142A (ja) 2023-05-02
TR201906650T4 (tr) 2019-05-21
CA2789154A1 (en) 2011-08-11
RS55315B2 (sr) 2020-08-31
KR102283195B1 (ko) 2021-07-29
IL267362B (en) 2022-02-01
JP2015171386A (ja) 2015-10-01
HRP20161551T1 (hr) 2016-12-30
LT3095871T (lt) 2019-05-27
HRP20191191T1 (hr) 2019-10-04
DK2501817T3 (en) 2015-12-07
PL2505654T5 (pl) 2020-11-30
JP6960005B2 (ja) 2021-11-05
LT2505654T (lt) 2016-12-12
MX2021000286A (es) 2022-06-08
AU2011213585A1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
CY1121794T1 (el) Ποντικος κοινης ελαφριας αλυσου
CY1124972T1 (el) Ποντικοι με περιορισμενη βαρια αλυσιδα ανοσοσφαιρινης
CY1122036T1 (el) Μη ανθρωπινα ζωα που εκφραζουν αντισωματα τα οποια εχουν μια κοινη ελαφρια αλυσιδα
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
CY1121102T1 (el) Αντισωματα που προσδενουν τον csf1r
CY1124090T1 (el) Συνθεσεις αντισωματων για τη θεραπεια ογκων
CY1122020T1 (el) Μορια δεσμευσης σε cd3 ικανα να δεσμευονται σε ανθρωπινα και μη ανθρωπινα cd3
CY1122091T1 (el) Μορια δεσμευσης-cd37 και ανοσοσυζευγματα εξ αυτων
CY1124472T1 (el) Κατασκευασματα διειδικων αντισωματων που δεσμευουν dll3 και cd3
CY1124358T1 (el) Ευκολως απομονωμενα διειδικα αντισωματα με φυσικης ανοσοσφαιρινης μορφη
CY1120770T1 (el) Ζωα πλην του ανθρωπου με τροποποιημενες αλληλουχιες βαριας αλυσιδας της ανοσοσφαιρινης
CY1123935T1 (el) Αντισωματα κατευθυνομενα εναντι προγραμματισμενου θανατου-1 (pd-1)
CY1122463T1 (el) Αγωγη των κυτταρων παθησεων cd47+ με συντηξεις sirp αλφα-fc
CY1118928T1 (el) Αντι-οχ40 αντισωματα και μεθοδοι χρησης τους
CY1121412T1 (el) ΚΑΤΑΣΚΕΥΑΣΜΕΝΑ ΑΝΤΙΣΩΜΑΤΑ ΕΝΑΝΤΙ ΤΟΥ TGF-β ΚΑΙ ΚΛΑΣΜΑΤΑ ΔΕΣΜΕΥΣΗΣ ΑΝΤΙΓΟΝΟΥ
CY1120412T1 (el) Μορια εξανθρωπισμενου αντισωματος ειδικα για il-31
ECSP17083779A (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos
MX360707B (es) Receptor antigénico quimérico.
SA517381604B1 (ar) أجسام مضادة ديمرية غير متجانسة جديدة
EA201690447A1 (ru) БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬСЯ С gpA33 И CD3, И ИХ ПРИМЕНЕНИЯ
AR114112A1 (es) Anticuerpos de glipicano 3 y conjugados de los mismos
BR112021026890A2 (pt) Composições de anticorpo para interromper biofilmes
CO6761352A2 (es) Anticuerpos neutralizadores anti-ccl20
BR112013002695A2 (pt) camundongos que produzem proteínas de ligação compreendendo domínios vl.
EA201992756A2 (ru) Антитела против cd48 и их конъюгаты